Evidence map›Paper›PMID 23652927›Full record

Trial reportDer Unfallchirurg2014

[Treatment of severe tibial fractures with extensive soft tissue damage and/or contamination. Quality of life after use of the Ilizarov external fixator].

D Baschera, C Walter, M Wren, R Zellweger

Abstract readClinical TrialEnglish Abstract
PubMed Publisher
In one paragraph

Trial report in Der Unfallchirurg, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Clinical outcomes and quality of life of patients after surgical treatment of a tibia plateau fracture.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

D BascheraDepartment of Orthopaedic and Trauma Surgery, Royal Perth Hospital, North block, Level 5, Wellington Street, 6000, Perth, WA, Australien, dbaschera@bluewin.ch.
C Walter
M Wren
R Zellweger
Royal Perth Hospital · AUSpitäler Schaffhausen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Ilizarov external fixator (IF) is an immediate and definitive treatment option for severe tibial fractures compromised by extensive soft tissue damage. The aim of this study was to assess the general performance of the IF and especially the impact on patient quality of life.

methodA postal questionnaire including an SF-12 health survey and questions about various other aspects of quality of life was sent to all patients who received an IF for primary fracture treatment at a level 1 trauma centre between January 2000 and June 2009.

resultsA total of 48 completed questionnaires were received from patients treated with IF for severe tibial fractures. The median time to removal of the IF was 154 days (range 70-614 days). The mean SF-12 mental component score (MCS) was 52 (SD±12) and the mean physical component score (PCS) was 38 (SD±11). Of the patients 100 % answered that they were either satisfied or very satisfied with the treatment and 91 % would choose the same method of treatment under similar circumstances.

conclusionsThis study demonstrates a high performance of IF in the treatment of severe tibial fractures with compromised soft tissue where more standard forms of treatment are contraindicated.

Indexed as

Patient SatisfactionAdolescentAdultAgedAged, 80 and overFemaleGermanyHumansIlizarov TechniqueMaleMiddle AgedQuality of LifeSoft Tissue InfectionsSoft Tissue InjuriesTibial FracturesTreatment Outcome

Identifiers

PMID23652927
OpenAlexW207110763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.